The US Food and Drug Administration (FDA) has approved gefurulimab-gaks (Klygefa), developed by Alexion, AstraZeneca Rare Disease, for adults with anti-acetylcholine receptor (AChR) antibody-positive generalized myasthenia gravis (gMG), introducing a once-weekly, self-administered complement C5 inhibitor for this population. AstraZeneca announced the approval on November 16.
The company describes gefurulimab as a dual-binding nanobody that inhibits complement protein C5, preventing formation of the membrane attack complex implicated in neuromuscular junction damage in AChR antibody-positive disease. It's binding to serum albumin extends its half-life, supporting weekly subcutaneous administration using an autoinjector or prefilled syringe.
Approval was supported by PREVAIL, a phase 3, randomized, double-blind, placebo-controlled trial involving 260 adults across 20 countries. Participants had AChR antibody-positive gMG, Myasthenia Gravis Foundation of America class II–IV disease, and a Myasthenia Gravis Activities of Daily Living (MG-ADL) score of at least 5. Patients received gefurulimab (n=131) or placebo (n=129) for 26 weeks while continuing eligible background therapies at stable doses.
The FDA-approved prescribing information identifies change from baseline in MG-ADL total score at week 26 as the primary endpoint. Scores improved by 4.2 points with gefurulimab vs 2.6 points with placebo (treatment difference, −1.6 points). AstraZeneca reported improvements beginning at week 1 and maintained through week 26.
The key secondary endpoint, Quantitative Myasthenia Gravis score, improved by 4.5 points with gefurulimab vs 2.4 points with placebo. At week 26, 65.5% of gefurulimab recipients achieved at least a 3-point MG-ADL improvement vs 52.2% receiving placebo.
In the same trial, injection-site reactions were reported in 12% of gefurulimab recipients vs 3% receiving placebo; back pain in 8% vs 2%, and vomiting in 5% vs 1%.
The FDA-approved dosing regimen specifies a 600-mg loading dose on day 1 for patients weighing less than 80 kg, followed by 300 mg once weekly from day 8. Those weighing 80 kg or more receive a 900-mg loading dose, followed by 600 mg weekly. Patients or caregivers can administer treatment after appropriate training.
The label carries a boxed warning for serious meningococcal infections and contraindicates treatment initiation in patients with unresolved serious Neisseria meningitidis infection. It requires meningococcal vaccination at least 2 weeks before treatment, with antibacterial prophylaxis when urgent treatment is necessary in patients not up to date with vaccination. Gefurulimab is available only through a restricted Risk Evaluation and Mitigation Strategy (REMS) requiring prescriber certification, patient counseling, and vaccination assessment.
Sources: AstraZeneca, FDA Prescribing Information
